Letter to the FDA Urging the Agency to Promptly Convene an Outside Expert Advisory Panel To Revisit the Decision to Approve Remdesivir for Treatment of COVID-19

View as PDF

View press release

Public Citizen called on the Food and Drug Administration (FDA) to promptly convene an external expert advisory panel to evaluate whether the approval of the antiviral COVID-19 treatment remdesivir should be rescinded. The FDA approved the drug despite being aware of evidence from a major clinical trial that raised substantial doubts about whether the drug provides clinically meaningful benefit and without convening a public advisory committee meeting, as the agency routinely does prior to approving such new drugs.

July 21, 2021, FDA response letter.

View Public Citizen’s other work on remdesivir.

See Public Citizen’s other work on the coronavirus pandemic.